


Ceftobiprole medocaril sodium

Cat. No.:	HY-106574A
CAS No.:	252188-71-9
Molecular Formula:	C ₂₆ H ₂₅ N ₈ NaO ₁₁ S ₂
Molecular Weight:	712.64
Target:	Bacterial
Pathway:	Anti-infection
Storage:	4°C, sealed storage, away from moisture and light * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)



SOLVENT & SOLUBILITY

In Vitro

DMSO : 250 mg/mL (350.81 mM; Need ultrasonic)

Concentration	Solvent	Mass		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	1.4032 mL	7.0162 mL	14.0323 mL
	5 mM	0.2806 mL	1.4032 mL	2.8065 mL
	10 mM	0.1403 mL	0.7016 mL	1.4032 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

Ceftobiprole medocaril (BAL5788) sodium is the parenteral proagent of Ceftobiprole (HY-112579). Ceftobiprole is a parenteral pyrrolidinone cephalosporin. Ceftobiprole is a broad-spectrum cephalosporin with high levels of in vitro activity against methicillin- (MRSA) and vancomycin-resistant staphylococci (VRSA) and penicillin-resistant streptococci. Ceftobiprole also inhibits gram-positive and gram-negative pathogens^{[1][2]}.

In Vivo

Ceftobiprole medocaril (s.c.; 3 × q12h; total daily doses of BAL9141 equivalents, 2.1, 4.2, or 8.4 mg/kg) causes ten-day cumulative survival rates ranged from 57 to 100% for female Swiss albino mice (body weight, 20 to 22 g) infected Pen^f Cro^s Ctx^s strain P-15986^[1].

Ceftobiprole medocaril (10, 40, 160 mg/kg; single dose; sc) has T_{1/2s} from 20 min to 31 min, as the dose rose from 40 mg/kg to 160 mg/kg. The AUC/dose values for the escalating single doses ranges from 0.585 to 1.33, and the C_{max}/dose values decreases from 1.08 to 0.90 in neutropenic thigh-infected mice^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. E Azoulay-Dupuis, et al. Efficacy of BAL5788, a prodrug of cephalosporin BAL9141, in a mouse model of acute pneumococcal pneumonia. *Antimicrob Agents Chemother.* 2004 Apr;48(4):1105-11.

[2]. W A Craig, et al. In vivo pharmacodynamics of ceftobiprole against multiple bacterial pathogens in murine thigh and lung infection models. *Antimicrob Agents Chemother.* 2008 Oct;52(10):3492-6.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA